Occurrence of comorbid diseases in patients after COVID-19

Abstract

The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence and characteristics of comorbidities in COVID-19 patients. We analyzed data from 220 patients who previously contracted COVID-19. Statistical analysis was performed using SPSS software. The average age of the patients was 54.6 ± 11.4 years, and arterial hypertension (AH) was the most common comorbidity, affecting 55% of patients. Obesity was observed in one-third of patients, while coronary heart disease (CHD) and coronary heart failure (CHF) were reported in 17.7% and 11.8% of patients, respectively. Chronic kidney disease (CKD), atrial fibrillation (AF), and obstructive pulmonary disease (COPD) were less common. Cardiovascular diseases, particularly AH, were the most frequent comorbidities in COVID-19 patients. Understanding the prevalence and characteristics of comorbidities in COVID-19 patients is crucial for developing appropriate management strategies and improving clinical outcomes. Our findings highlight the importance of identifying and managing comorbidities in COVID-19 patients to reduce the risk of severe COVID-19 and improve clinical outcomes.

Immune response variation in mild and severe COVID-19 patients

“…Comparative studies have shown the potential to investigate the immunological status across various groups of COVID-19 patients, including those with differing disease severities and even asymptomatic or healthy individuals. 28 In a study conducted by Wiech et al, they examined a group of patients who experienced a severe course of coronavirus infection. 29 Their findings revealed a significant increase in the number of final effector cells CD8+ CD57+ six months after infection, accompanied by a substantial reduction in the population of naïve T-cells.…”

Evaluation of indicators of coagulation hemostasis and endothelial dysfunction in covid-19 convalescents

“…Studies to assess the clinical course of the disease, complications, clinical and functional features of comorbid conditions in patients with COVID-19 are focused on identifying new aspects and early signs of etiopathogenesis by studying specific biomarkers and molecular genetic factors; scientific research is being carried out to develop a methodology for early detection and prediction of the risk of complications of the disease [6,7,13]. Direct and indirect damage to SARS-CoV-2 endothelial cells in patients with COVID-19 increases the activity of the reninangiotensin-aldosterone system (RAAS), which increases the risk of worsening the course of the disease and developing an unfavorable prognosis [8,9,11]. In a multicenter cohort study, elevated levels of endothelial dysfunction biomarkers, RAAS hormones, in patients with COVID-19 were associated with an increased risk of death and poor prognosis [10,12].…”